Leonid Aleksandrovich Klarov

Dr. Leonid Aleksandrovich Klarov


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LKLeonid Aleksandrovich Klarov
Leonid Aleksandrovich Klarov
VPVera G. Pshennikova
Vera G. Pshennikova
GRGeorgii Romanov
Georgii Romanov
ACAleksandra M. Cherdonova
Aleksandra M. Cherdonova
ASAisen V. Solovyev
Aisen V. Solovyev
NBNikolay Barashkov
Nikolay Barashkov
Pathogenic variants in the SLC26A4, FOXI1, and KCNJ10 genes are associated with hearing loss (HL) and specific inner ear abnormalities (DFNB4). In the present study, phenotype analyses, including clinical data collection, computed tomography (CT), and audiometric examination, were performed on deaf individuals from the Sakha Republic of Russia (Eastern Siberia). In cases with cochleovestibular malformations, molecular genetic analysis of the coding regions of the SLC26A4, FOXI1, and KCNJ10 genes associated with DFNB4 was completed. In six of the 165 patients (3.6%), CT scans revealed an incomplete partition of the cochlea (IP-1 and IP-2), in isolation or combined with an enlarged vestibular aqueduct (EVA) anomaly. Sequencing of the SLC26A4, FOXI1, and KCNJ10 genes was performed in these six patients. In the SLC26A4 gene, we identified four variants, namely c.85G>C p.(Glu29Gln), c.757A>G p.(Ile253Val), c.2027T>A p.(Leu676Gln), and c.2089+1G>A (IVS18+1G>A), which are known as pathogenic, as well as c.441G>A p.(Met147Ile), reported previously as a variant with uncertain significance. Using the AlphaFold algorithm, we found in silico evidence of the pathogenicity of this variant. We did not find any causative variants in the FOXI1 and KCNJ10 genes, nor did we find any evidence of digenic inheritance associated with double heterozygosity for these genes with monoallelic SLC26A4 variants. The contribution of biallelic SLC26A4 variants in patients with IP-1, IP-2, IP-2+EVA, and isolated EVA was 66.7% (DFNB4 in three patients, Pendred syndrome in one patient). Seventy-five percent of SLC26A4-biallelic patients had severe or profound HL. The morphology of the inner ear anomalies demonstrated that, among SLC26A4-biallelic patients, all types of incomplete partition of the cochlea are possible, from IP-1 and IP-2, to a normal cochlea. However, the dominant type of anomaly was IP-2+EVA (50.0%). This finding is very important for cochlear implantation, since the IP-2 anomaly does not have an increased risk of “gushers” and recurrent meningitis.

17 April 2023 in Nauchno-prakticheskii zhurnal «Medicinskaia genetika»
Verified
Journal Article
Open access
PDF file
LKLeonid Aleksandrovich Klarov
Leonid Aleksandrovich Klarov
ВПВ. Г. Пшенникова
В. Г. Пшенникова
ФТФ. М. Терютин
Ф. М. Терютин
НЛН. В. Лугинов
Н. В. Лугинов
ПКП. М. Котляров
П. М. Котляров
НБН. А. Барашков
Н. А. Барашков
Синдром CHARGE – редкое аутосомно-доминантное заболевание, вызванное мутационными повреждениями в генах CHD7 и SEMA3E (OMIM 214800). Распространенность составляет примерно 1 случай на 12000 новорожденных. Большинство случаев синдрома CHARGE обусловлено de novo патогенными вариантами гена CHD7, кодирующего ДНК-связывающий белок хромодомена хеликазы 7, который ответственен за организацию хроматина. Аббревиатура «CHARGE» обобщает шесть клинических признаков синдрома: С (coloboma) – глазная колобома, H (heart defects) – пороки сердца, A (atresia of choanae) – атрезия хоан, R (retardation of growth) – задержка роста и / или развития, G (genital anomalies) – аномалии гениталий, E (ear abnormalities) – аномалии уха. В настоящей работе представлен клинический случай с ранее не описанной нонсенс заменой c.1940C>G (p.Ser647*) в гене CHD7, выявленной методом полноэкзомного секвенирования у пациента с недифференцированной формой потери слуха и множественными аномалиями развития. В результате клинико-генетического обследования у пациента выявлено 7 признаков, соответствующих обновленным диагностическим критериям синдрома CHARGE: три основных (аномалии внутреннего уха, глазная колобома и патогенные мутации в гене CHD7) и четыре второстепенных признака (задержка умственного развития, врожденный порок сердца, гипоталамо-гипофизарная дисфункция и дисфункция черепных нервов). В работе обсуждается связь с данным синдромом выявленных двух дополнительных признаков со стороны опорно-двигательного аппарата и эндокринной системы, не включенных в последнюю версию диагностических критериев синдрома CHARGE. Мы надеемся, что пристальное внимание к генотип-фенотипическим особенностям поможет определить, как лучше диагностировать, консультировать и оказывать необходимую медицинскую и социальную помощь пациентам с подобными редкими заболеваниями. CHARGE syndrome is a rare autosomal dominant disease caused by mutational lesions in the CHD7 and SEMA3E genes (OMIM 214800). The prevalence is approximately 1 in 12,000 newborns. Most cases of CHARGE syndrome are caused by de novo pathogenic variants of the CHD7 gene, which encodes the DNA-binding protein helicase 7 chromodomain, which is responsible for chromatin organization. The abbreviation “CHARGE” summarizes six clinical signs of the syndrome: C - coloboma, H - heart defects, A - atresia of choanae, R - retardation of growth and/or development, G - genital anomalies, E - ear abnormalities. This paper presents a genotype-phenotypic analysis of a case with a previously unknown nonsense substitution c.1940C>G (p.Ser647*) in the CHD7 gene, identified by whole exome sequencing in a patient with an initially undifferentiated form of hearing loss associated with multiple developmental anomalies. As a result of a clinical examination, the patient revealed 7 signs that correspond to the updated diagnostic criteria for CHARGE syndrome: three main ones (anomalies of the inner ear, ocular coloboma and pathogenic variant in the CHD7 gene) and four secondary signs (mental retardation, congenital heart disease, cranial nerve dysfunction, hypothalamic-pituitary dysfunction). The paper discusses the relationship with this syndrome of the identified two additional signs from the endocrine system and the musculoskeletal system, not included in the latest version of the diagnostic criteria for the CHARGE syndrome. We hope that close attention to genotype-phenotypic characteristics will help determine how best to diagnose, counsel and provide the necessary medical and social care for patients with such rare diseases.